Expression of miRNAs in Papillary Thyroid Carcinomas is Associated with BRAF Mutation and Clinicopathogenetic Features in a Cohort of Chinese Patients

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: MON 414-436-HPT Axis Biology & Action
Basic/Translational
Monday, June 17, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board MON-431
Shuang Yu* and Haipeng Xiao
First Affiliated Hospital, Sun Yat-sen University, China
Objective: In recent years, microRNAs (miRNAs) dysregulation has been showed to play a critical regulatory role in various cancers, including papillary thyroid carcinomas (PTC). BRAF mutation is associated with poor clinicopathological outcomes in PTC. The aim of this study was to identify a possible correlation between dysregulated miRNA expression and BRAF mutation as well as clinicopathogenetical features in a cohort of Chinese PTC patients.

Methods: The expression levels of five reported dysregulated miRNAs (miRNA-221, miRNA-222,miRNA-146b, miRNA-181 and miRNA-21) were examined by quantitative real time polymerase chain reaction (qRT-PCR) in 52 patients with PTC and 52 patients with benign thyroid nodules (BTN). BRAF mutation status was determined using DNA-sequencing method. The association between the expression of miRNAs with BRAF mutation and a variety of clinicopathogenetical data was analyzed.

Results: The expression levels of miRNA-221, miRNA-222,miRNA-146b, miRNA-181 and miRNA-21 were significantly increased in PTC when compared to BTN. All of these five miRNAs could be used to differentiate PTC from BTN, with miRNA-146b yielding the largest area under the receiver operator characteristic (ROC) curve of 0.952 with 90.4% sensitivity and 88.5% specificity. The BRAF mutation occurred more frequently in PTC cases with advanced TNM stage. Importantly, miRNA-221, miRNA-222, miRNA-146b and miRNA-181 expression levels were significantly higher in PTC patients with BRAF mutation. In addition, enhanced expression of miRNA-221 and miRNA-222 were associated with cervical lymph node metastasis and advanced TNM stage, while patients with larger tumors had increased expression of miRNA-221 and miR-181.

Conclusion: Our study showed a potential role of this distinct profile of miRNAs in differentiating PTC from BTN. BRAF mutation might regulate or interact with miRNA-221, miRNA-222 and miRNA 146b in the pathogenesis and progression of PTC.

Nothing to Disclose: SY, HX

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm

Sources of Research Support: This study was supported by National Natural Science Foundation of China (81072184).